The dangers of skin-lightening creams

Toxicological and Environmental Chemistry

Volumn 94, Issue 1, 2012, Pages 195-219

  Al Saleh, Iman ^a   Elkhatib, Rola ^a   Al Rouqi, Reem ^a   Al Enazi, Sami ^a   Shinwari, Neptune ^a  

^a KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

Author keywords

corticosteroids; hydroquinone; mercury; skin lightening creams; titanium

Indexed keywords

ACTIVE INGREDIENTS; ADVERSE EFFECT; COLOR ADDITIVES; CORTICOSTEROIDS; DEXAMETHASONES; HYDROQUINONE; LOW POTENCY; MERCURY CONTENT; PERSONAL CARE PRODUCTS; PERSONAL PRODUCTS; SAFETY LIMITS; SKIN-LIGHTENING CREAMS; TOXIC INGREDIENTS;

COMMERCE; KETONES; LIPIDS; MERCURY (METAL); OXIDES; PHENOLS; TITANIUM; TITANIUM DIOXIDE;

DRUG PRODUCTS;

CHEMICAL COMPOSITION; COHORT ANALYSIS; DECADAL VARIATION; DRUG; EUROPEAN UNION; HEALTH RISK; LACTATION; MERCURY (ELEMENT); PREGNANCY; SKIN; TITANIUM; TOXIC SUBSTANCE; WOMENS HEALTH;

SAUDI ARABIA;

EID: 84858312644     PISSN: 02772248     EISSN: 10290486     Source Type: Journal    
DOI: 10.1080/02772248.2011.631925     Document Type: Article

References (73)

1. Abraham, G, Gottschalk, J and Ungemach, FR. 2005. Evidence for ototopical glucocorticoid-induced decrease in hypothalamic-pituitary-adrenal axis response and liver function. Endocrinology, 146: 3163-71.
2. AlGhamdi, KM. 2010. The use of topical bleaching agents among women: A cross-sectional study of knowledge, attitude and practices. Journal of the European Academy of Dermatology & Venereology, 24: 1214-19.
3. Al-Saleh, I and Al-Doush, I. 1997. Mercury content in skin-lightening creams and potential hazards to the health of Saudi Women. Journal of Toxicology & Environmental Health, 51: 123-30.
4. Al-Saleh, I, Shinwari, N, El-Doush, I, Billedo, G, Al-Amodi, M and Khogali, F. 2004. Comparison of mercury levels in various tissues of albino and pigmented mice treated with two different brands of mercury skin-lightening creams. BioMetals, 17: 167-75.
5. Andersen, FA, Bergfeld, WF, Belsito, DV, Hill, RA, Klaassen, CD, Liebler, DC, Marks, J.G. Jr, Shank, RC, Slaga, TJ and Snyder, PW. 2010. Final amended safety assessment of hydroquinone as used in cosmetics. International Journal of Toxicology, 29: 274-87.
6. Antoniou, C, Kosmadaki, MG, Stratigos, AJ and Katsambas, AD. 2008. Sunscreens - What's important to know. Journal of the European Academy of Dermatology & Venereology, 22: 1110-18.
7. Barr, RD, Woodger, BA and Rees, PH. 1973. Levels of mercury in urine correlated with the use of skin lightening creams. American Journal of Clinical Pathology, 59: 36-40.
8. Bose-O'Reilly, S, McCarty, KM, Steckling, N and Lettmeier, B. 2010. Mercury exposure and children's health. Current Problems in Pediatric and Adolescent Health Care, 40: 186-215.
9. Boyd, AS, Seger, D, Vannucci, S, Langley, M, Abraham, JL and King Jr, LE. 2000. Mercury exposure and cutaneous disease. Journal of the American Academy of Dermatology, 43: 81-90.
10. Boyle, J and Kennedy, CT. 1985. Leukoderma from hydroquinone. Contact Dermatitis, 13: 287-8.
11. Browne, F and Wilkinson, SM. 2011. Effective prescribing in steroid allergy: controversies and cross-reactions. Clinical Dermatology, 29: 287-94.
12. Carretero, MI and Pozo, M. 2010. Clay and non-clay minerals in the pharmaceutical and cosmetic industries: Part II. Active ingredients. Applied Clay Science, 46: 171-81.
13. Choksi, AN, Poonawalla, T and Wilkerson, MG. 2010. Nanoparticles: A closer look at their dermal effects. Journal of Drugs Dermatology, 9: 475-81.
14. Clarkson, TW. 1997. The toxicology of mercury. Critical Review of Clinical Laboratory Sciences, 34: 369-403.
15. Dadzie, OE and Petit, A. 2009. Skin bleaching: highlighting the misuse of cutaneous depigmenting agents. Journal of the European Academy of Dermatology & Venereology, 23: 741-50.
16. DeCaprio, AP. 1999. The toxicology of hydroquinone - Relevance to occupational and environmental exposure. Critical Review Toxicology, 29: 283-330.
17. Draelos, ZD. 2007. Skin lightening preparations and the hydroquinone controversy. Dermatologic Therapy, 20: 308-13.
18. Draelos, ZD, Yatskayer, M, Bhushan, P, Pillai, S and Oresajo, C. 2010. Evaluation of a kojic acid, emblica extract, and glycolic acid formulation compared with hydroquinone 4% for skin lightening. Cutis, 86: 153-8.
19. Dyall-Smith, DJ and Scurry, JP. 1990. Mercury pigmentation and high mercury levels from the use of a cosmetic cream. Medical Journal of Australia, 153: 409-15.
20. Findlay, GH and de Beer, HA. 1980. Chronic hydroquinone poisoning of the skin from skin-lightening cosmetics. A South African epidemic of ochronosis of the face in dark-skinned individuals. South African Medical Journal, 57: 187-90.
21. Fisher, AA. 1998. Exogenous ochronosis from hydroquinone bleaching cream. Cutis, 62: 11-12.
22. Freyre-Fonseca, V, Delgado-Buenrostro, NL, Madrid, EB, Calderón-Torres, CM, Cabellos-Avelar, T, Sánchez-Pérez, YPinzón, E. 2011. Titanium dioxide nanoparticles impair lung mitochondrial function. Toxicological Letters, 202: 111-19.
23. Gao, X., S. Yin, M. Tang, J. Chen, Z. Yang, W. Zhang, L. Chen, et al. 2011. Effects of developmental exposure to TiO(2) nanoparticles on synaptic plasticity in hippocampal dentate gyrus area: An in vivo study in anesthetized rats. Biological Trace Elements Research. 2011 Feb 18
24. Gaudiano, MC, Lucente, D, Antoniella, E, Bertocchi, P, Muleri, N, Manna, L, Bartolomei, M, Alimonti, S, Valvo, L and Rodomonte, AL. 2010. "For export only" medicines come back to Europe: A RP-LC method for the screening of six glucocorticoids in illegal and counterfeit anti-inflammatory and lightening creams. Journal of Pharmacology and Biomedical Analysis, 53: 158-64.
25. Gottschalk, J., A. Einspanier, F.R. Ungemach, and G. Abraham. 2011. Influence of topical dexamethasone applications on insulin, glucose, thyroid hormone and cortisol levels in dogs. Research in Veterinary Science 90: 491-7
26. Gras, G and Mondain, J. 1981. The problem of the use of mercurials cosmetics in Senegal. Toxicological European Research, 3: 175-8.
27. Gustafsson, S, Lindstedt, E, Elfsmark, LS and Bucht, A. 2011. Lung exposure of titanium dioxide nanoparticles induces innate immune activation and long-lasting lymphocyte response in the Dark Agouti rat. Journal of Immunotoxicology, 8: 111-21.
28. Hájková, R, Solich, P, Dvorák, J and Sícha, J. 2003. Simultaneous determination of methylparaben, propylparaben, hydrocortisone acetate and its degradation products in a topical cream by RP-HPLC. Journal of Pharmacology and Biomedical Analaysis, 32: 921-7.
29. Hengge, UR, Ruzicka, T, Schwartz, RA and Cork, MJ. 2006. Adverse effects of topical glucocorticosteroids. Journal of the American Academy of Dermatology, 54: 1-15.
30. IARC, International Agency for Research on Cancer. 2006. Titanium dioxide (IARC Group 2B), Summary of data reported, February 2006
31. Iavicoli, I, Leso, V, Fontana, L and Bergamaschi, A. 2011. Toxicological effects of titanium dioxide nanoparticles: A review of in vitro mammalian studies. European Review of Medical Pharmacological Sciences, 15: 481-508.
32. Jin, CY, Zhu, BS, Wang, XF and Lu, QH. 2008. Cytotoxicity of titanium dioxide nanoparticles in mouse fibroblast cells. Chemical Research in Toxicology, 21: 1871-7.
33. Kamm, GL and Hagmeyer, KO. 1999. Allergic-type reactions to corticosteroids. Annals of Pharmacotherapy, 33: 451-60.
34. Karamagi, C, Owino, E and Katabira, ET. 2001. Hydroquinone neuropathy following use of skin bleaching creams: Case report. East African Medical Journal, 78: 223-4.
35. Keane, FM, Munn, SE, Vivier, AW, Higgins, EM and Taylor, NF. 1999. Analysis of Chinese herbal creams prescribed for dermatological conditions. Western Journal of Medicine, 170: 257-9.
36. Kooyers, TJ and Westerhof, W. 2004. Toxicological aspects and health risks associated with hydroquinone in skin bleaching formula. Nederlands tijdschrift voor geneeskunde, 148: 768-71.
37. Kuo, CY and Wu, SM. 2005. Micellar electrokinetic chromatography for simultaneous determination of six corticosteroids in commercial pharmaceuticals. Journal of Separation Science, 28: 144-8.
38. Ladizinski, B, Mistry, N and Kundu, RV. 2011. Widespread use of toxic skin lightening compounds: Medical and psychosocial aspects. Dermatological Clinics, 29: 111-23.
39. Lai, JC, Lai, MB, Jandhyam, S, Dukhande, VV, Bhushan, A, Daniels, CK and Leung, SW. 2008. Exposure to titanium dioxide and other metallic oxide nanoparticles induces cytotoxicity on human neural cells and fibroblasts. International Journal of Nanomedicine, 3: 533-45.
40. Li, SQ, Zhu, RR, Zhu, H, Xue, M, Sun, XY, Yao, SD and Wang, SL. 2008. Nanotoxicity of TiO(2) nanoparticles to erythrocyte in vitro. Food & Chemical Toxicology, 46: 3626-31.
41. Luderschmidt, C and Plewig, G. 1979. Chronic mercury poisoning following topical application of skin bleachers. Klinische Wochenschrift, 57: 293-8.
42. Mahé, A, Ly, F, Aymard, G and Dangou, JM. 2003. Skin diseases associated with the cosmetic use of bleaching products in women from Dakar, Senegal. British Journal of Dermatology, 148: 493-500.
43. Mahé, A, Perret, JL, Ly, F, Fall, F, Rault, JP and Dumont, A. 2007. The cosmetic use of skin-lightening products during pregnancy in Dakar, Senegal: A common and potentially hazardous practice. Transactions Royal Society of Tropical Medicine Hygiene, 101: 183-7.
44. Martín, RF, Sánchez, JL, González, A, Lugo-Somolinos, A and Ruiz, H. 1992. Exogenous ochronosis. P R Health Science Journal, 11: 23-6.
45. McKelvey, W, Jeffery, N, Clark, N, Kass, D and Parsons, PJ. 2011. Population-based inorganic mercury biomonitoring and the identification of skin care products as a source of exposure in New York city. Environmental Health Perspectives, 119: 203-9.
46. Menter, A. 2004. Rationale for the use of topical corticosteroids in melasma. Journal of Drugs in Dermatology, 3: 169-74.
47. Nnoruka, E and Okoye, O. 2006. Topical steroid abuse: its use as a depigmenting agent. Journal National Medicine Association, 98: 934-9.
48. Nohynek, GJ, Lademann, J, Ribaud, C and Roberts, MS. 2007. Grey goo on the skin? Nanotechnology, cosmetic and sunscreen safety. Critical Reviews in Toxicology, 37: 251-77.
49. Olumide, YM, Akinkugbe, AO, Altraide, D, Mohammed, T, Ahamefule, N, Ayanlowo, S, Onyekonwu, C and Essen, N. 2008. Complications of chronic use of skin lightening cosmetics. International Journal of Dermatology, 47: 344-53.
50. Otto, M, Ahlemeyer, C, Tasche, H and von Mühlendahl, KE. 1994. Endemic mercury burden caused by a bleaching ointment in Balken refugees. Gesundheitswesen, 56: 686-9.
51. Ozkaya, E, Mirzoyeva, L and Otkur, B. 2009. Mercury-induced systemic allergic dermatitis caused by 'white precipitate' in a skin lightening cream. Contact Dermatitis, 60: 61-3.
52. Palmer, RB, Godwin, DA and McKinney, PE. 2000. Transdermal kinetics of a mercurous chloride beauty cream: An in vitro human skin analysis. Journal of Toxicology-Clinical Toxicology, 38: 701-7.
53. Park, EJ, Yoon, J, Choi, K, Yi, J and Park, K. 2009. Induction of chronic inflammation in mice treated with titanium dioxide nanoparticles by intratracheal instillation. Toxicology, 260: 37-46.
54. Park, H and Kim, K. 2011. Association of blood mercury concentrations with atopic dermatitis in adults: A population-based study in Korea. Environmental Research, 111: 573-8.
55. Pellegrini, M, Marchei, E, Pacifici, R, Concetta Rotolo, M and Pichini, S. 2011. Advances in the analysis of non-allowed pharmacologically active substances in cosmetic products. Journal of Pharmaceutical and Biomedical Analysis, 55: 842-7.
56. Peregrino, CP, Moreno, MV, Miranda, SV, Rubio, AD and Leal, LO. 2011. Mercury levels in locally manufactured Mexican skin-lightening creams. International Journal of Environmental Research and Public Health, 8: 2516-23.
57. Pinnell, SR, Fairhurst, D, Gillies, R, Mitchnick, MA and Kollias, N. 2000. Microfine zinc oxide is a superior sunscreen ingredient to microfine titanium dioxide. Dermatologic Surgery, 26: 309-14.
58. Rapaport, MJ and Mark Lebwohl, M. 2003. Corticosteroid addiction and withdrawal in the atopic: The red burning skin syndrome. Clinics in Dermatology, 21: 201-14.
59. Rueda, ME, Sarabia, LA, Herrero, A and Ortiz, MC. 2003. Optimisation of a flow injection system with electrochemical detection using the desirability function: Application to the determination of hydroquinone in cosmetics. Analytica Chimica Acta, 479: 173-84.
60. SCCNFP, Scientific Committee on Cosmetic Products and Non-Food Products intended for consumers. Titanium dioxide, Colipa n° S75. Adopted by the SCCNFP during the 14th plenary meeting of 24 October 2000.http://ec.europa.eu/health/ph_risk/committees/sccp/documents/out135_en.pdf
61. Sin, KW and Tsang, HF. 2003. Large-scale mercury exposure due to a cream cosmetic: Community-wide case series. Hong Kong Medical Journal, 9: 329-34.
62. Soo, YO, Chow, KM, Lam, CW, Lai, FM, Szeto, CC, Chan, MH and Li, PK. 2003. A whitened face woman with nephrotic syndrome. American Journal of Kidney Disorders, 41: 250-3.
63. Summa, JD. 1975. Chronic mercury poisoning from cosmetic creams. Münchener Medizinische Wochenschrift, 117: 1121-4.
64. Tse, TW. 2010. Hydroquinone for skin lightening: Safety profile, duration of use and when should we stop?. Journal of Dermatological Treatment, 21: 272-5.
65. US FDA, Code of Federal Regulations. Food and Drug Administration Department of Health and Human Services. Subchapter A-General. 1966a. Title 21, volume 1: Food and Drugs. PART 73 - LISTING OF COLOR ADDITIVES EXEMPT FROM CERTIFICATION. Subpart A - Foods. §73.575 Titanium dioxide.http://ecfr.gpoaccess.gov/cgi/t/text/text-idx?c=ecfr&sid=f8b028bb0ebc00570790e3a5eb78879c&rgn=div8&view=text&node=21:1.0.1.1.26.1.31.34&idno=21
66. US FDA, Code of Federal Regulations. Food and Drug Administration Department of Health and Human Services. Subchapter A-General. 1966b. Title 21, volume 1: Food and Drugs. PART 73 - LISTING OF COLOR ADDITIVES EXEMPT FROM CERTIFICATION. Subpart B - Drugs. §73.1575 Titanium dioxide.http://ecfr.gpoaccess.gov/cgi/t/text/text-idx?c=ecfr&sid=1dc9c8cc490b2823b192b7b4bba42b34&rgn=div8&view=text&node=21:1.0.1.1.26.2.31.26&idno=21
67. US FDA, Code of Federal Regulations. Food and Drug Administration Department of Health and Human Services. Subchapter A-General. 1973. Title 21, volume 1: Food and Drugs. PART 73 - LISTING OF COLOR ADDITIVES EXEMPT FROM CERTIFICATION. Subpart C - Cosmetics. § 73.2575 Titanium dioxide.http://ecfr.gpoaccess.gov/cgi/t/text/text-idx?c=ecfr;sid=d4fd16458054c9a8acb026cf36626a19;rgn=div8;view=text;node=21%3A1.0.1.1.26.3.31.22;idno=21;cc=ecfr
68. US FDA, Code of Federal Regulations. Food and Drug Administration Department of Health and Human Services. 2011. Part 700-General. Subpart B-Requirements for specific cosmetic products. 700.13 Use of mercury compounds in cosmetics including use as skin bleaching agents in cosmetic preparations also regarded as drugs.http://ecfr.gpoaccess.gov/cgi/t/text/text-idx?c=ecfr&sid=f13aab9a2029c16e3ccc95dbf19ecb30&rgn=div8&view=text&node=21:7.0.1.2.10.2.1.2&idno=21
69. US FDA, Code of Federal Regulations. Food and Drug Administration Department of Health and Human Services. 1999b. Subpart B - Requirements for Specific Cosmetic Products. §700.35 Cosmetics containing sunscreen ingredients.http://ecfr.gpoaccess.gov/cgi/t/text/text-idx?c=ecfr;sid=fa46a428e7265e60dcf3354fd5b25b2d;rgn=div5;view=text;node=21%3A7.0.1.2.10;idno=21;cc=ecfr#21:7.0.1.2.10.2.1.11
70. US FDA, Food and Drug Administration and Health and Human Services. 1999a. Sunscreen drug products for over-the-counter human use; final monograph. Final rule. Federal Register, 64: 27666-93.
71. US FDA, Food and Drug Administration and Health and Human Services. 2006. 21 CFR Part 310. Skin bleaching drug products for over-the-counter human use; proposed rule. Federal Register 71: 51146-55.http://www.fda.gov/OHRMS/DOCKETS/98fr/E6-14263.htm
72. US FDA, Food and Drug Administration and Health and Human Services. 2007. Nanotechnology Task Force Report 2007.http://www.fda.gov/ScienceResearch/SpecialTopics/Nanotechnology/NanotechnologyTaskForceReport2007/default.htm
73. Wiedersberg, S, Leopold, CS and Guy, RH. 2008. Bioavailability and bioequivalence of topical glucocorticoids. European Journal of Pharmaceutics and Biopharmaceutics, 68: 453-66.